Emily Mullin

Biography for Emily Mullin

Emily Mullin, Associate Editor

Before joining the Fierce life sciences team as an associate editor, Emily Mullin was a reporter at the Baltimore Business Journal, where she covered the healthcare and biotechnology industries, and a staff writer for Dorland Health, a healthcare trade publishing company based in Rockville, MD. She has served as a contributing writer to The Maryland Daily Record, where she’s covered topics ranging from neuroscience to hospital consolidation. Her business and healthcare stories have also appeared in Nephrology Times, Columbus Business First and the Cincinnati Business Courier. She is based in Washington, DC, and is a graduate of the E.W. Scripps School of Journalism at Ohio University. You can contact her at emullin@fiercemarkets.com and follow her on Twitter at @EmilyMFierce.

Articles by Emily Mullin

SARS enzyme finding could help advance MERS vaccine

In an important step toward the creation of a vaccine against deadly coronaviruses, researchers from Purdue University have figured out how to disable a key enzyme of the SARS virus that helps it hide from the immune system.

Scripps, U. of Nebraska-Lincoln win $15M to advance HIV vaccines

The Scripps Research Institute has landed a $13 million grant from the National Institute of Allergy and Infectious Diseases to advance antibodies toward the development of an HIV vaccine. Meanwhile, another team of researchers at the University of Nebraska-Lincoln has won nearly $2 million for its experimental HIV vaccine.

Study: Cholera vaccine has 86% effectiveness rate

Two doses of the oral cholera vaccine Shanchol provided an 86% percent protection rate during a recent outbreak in Guinea, according to a new study.

Study: Only 50% of Canadian healthcare workers are vaccinated

A new analysis published in the Canadian Medical Association Journal shows that vaccination rates among healthcare workers in Canada are less than 50%, well below the level necessary for herd immunity.

ASCO preview: What's the outlook for cancer vaccines?

The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.

Pandemic flu vaccine research poses risk of unintended release

Virulent flu strains pose the danger of potential release, even when used in experiments for vaccine research, and investigators from the Harvard and Yale universities are calling for greater scrutiny of such studies.

Sanofi C. diff vaccine shows immune response in PhII trial

BOSTON--Sanofi's Phase II trial results for its Clostridium difficile vaccine are proof that the French drug giant is leading the race for preventive therapies for the deadly bacterial infection.

Computer model can boost child vaccination rates while cutting costs

Software developed by researchers at the University of Pittsburgh and Johns Hopkins University has helped the Republic of Benin in West Africa deliver more vaccines to children most in need, according to a new study.

People most in need of Merck's shingles jab often not vaccinated

Not enough people are being vaccinated against shingles, and those who are at the highest risk for the painful viral infection, such as those with immunosuppressive disorders like HIV, are not able to receive the vaccine because of safety issues, according to a new study.

Glaxo, Sanofi ready to supply vaccines amid polio emergency

In light of news that polio has once again emerged as a public health emergency, vaccinemakers GlaxoSmithKline and Sanofi are reportedly on watch.